Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO to Scale Patient Access to Radiopharmaceutical Therapies
Hahn joins Nucleus RadioPharma after serving as CEO-partner of Flagship Pioneering and CEO of Harbinger Health since 2021. He served as the 24th U.S. Food and Drug Administration (FDA) commissioner from 2019 to 2021, overseeing both COVID and non-COVID regulatory affairs. Before joining the FDA, he was the chief medical executive at MD Anderson Cancer Center in Houston. The combination of regulatory, clinical and operational knowledge gives him deep insight into how therapies move from clinic to patient.
Radiopharmaceuticals represent one of the most promising frontiers in oncology, offering treatments that are less toxic, less invasive and far more precise in targeting cancer cells. When patients receive these therapies, outcomes improve and quality of life is preserved. However, widespread access to radiopharmaceuticals remains extremely limited, not due to scientific barriers, but logistical ones. Three interdependent issues drive these supply chain challenges: a fragile and insufficient supply of key isotopes, limited GMP-compliant infrastructure capable of handling a range of medical isotopes and an underdeveloped operational capacity to manage radioactive drugs.
'Radiopharmaceuticals are the next frontier of precision oncology care,' said Hahn. 'But without the infrastructure to deliver these treatments, their impact is fundamentally limited. At Nucleus RadioPharma, we have an extraordinary team that is committed to breaking those barriers. Together, we will scale the systems and infrastructure needed to make these lifesaving therapies available to all who need them.'
Under Hahn's leadership, Nucleus RadioPharma is uniquely positioned to tackle these issues, take radiopharmaceuticals to new levels of precision and efficacy and make minimally invasive therapies the new standard for cancer treatment.
'Steve's experience as both a physician treating patients and as a leader at the FDA brings an unparalleled perspective to Nucleus as the company works to build the infrastructure needed to accelerate the widespread availability of radiopharmaceuticals,' said Justin Butler, partner at Eclipse and Nucleus board member. 'His new role is a major indicator to the oncology community that radiopharmaceuticals are the future of precision cancer treatment, and that Nucleus is poised to lead the next era.'
Founded in 2022 through a collaboration between Eclipse and Mayo Clinic, Nucleus has raised $72 million in funding to date, including participation from AstraZeneca. The company is building a network of advanced facilities, starting in Mesa, Arizona, and Spring House, Pennsylvania, that integrate research, development and commercial-scale production under one roof, enabling faster, more reliable distribution to clinical trial sites and treatment centers.
'With one of the largest cancer theranostics practices in the world, we have a responsibility to drive continual innovation and develop new targeted diagnostic and therapeutic radioisotopes for our patients,' said Dr. Cheryl Willman, Stephen and Barbara Slaggie executive director for Mayo Clinic Cancer Programs and Mayo Clinic Comprehensive Cancer Center. 'With Steve's exemplary leadership skills and expertise as a cancer physician and scientist, our future could not be brighter.'
In his first year as CEO, Hahn will focus on completing the company's GMP readiness at its Rochester, Minnesota, facility, expanding R&D capabilities, launching Nucleus' data platform and forging strategic partnerships. Over the next five years, the company aims to dramatically increase manufacturing capacity and advance initiatives that improve patient access worldwide.
For more information on Nucleus RadioPharma, see here.
Nucleus RadioPharma is an innovative CDMO dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, Nucleus provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Its technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization. Learn more at https://nucleusrad.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Homebuilders Offer Best Incentives Since COVID
Homebuilders are doing just about everything they can to make a sale. Buyers remain scarce. In fact, builders are offering the most sales incentives in five years, according to the National Association of Home Builders' (NAHB) monthly confidence index data released Monday, which also showed that builders' confidence in the market is now at its lowest level since late 2022. Both builders and buyers, however, may take solace knowing that the Oracle of Omaha, in one of his final prophecies, foresees upside for the sector. READ ALSO: SoftBank Acquires a 2% Stake in Embattled Intel and Brokers Chafe Under Abrupt Expansion of Steel, Aluminum Tariffs Buffett-Backed Real Estate Just how desperate are homebuilders to move inventory? A full 37% have slashed prices this month, down ever so slightly from 38% in July — the highest figure since the NAHB started tracking the data in 2022. In both months, the average price reduction was 5%; that comes after the median sale price of existing homes hit an all-time high earlier this summer, according to the National Association of Realtors. Some 66% of builders are offering sales incentives in some form or another, up from 62% last month and the highest since the COVID-19 pandemic. Shop Top Mortgage Rates A quicker path to financial freedom Personalized rates in minutes Your Path to Homeownership Worse, 'builders are also grappling with supply-side headwinds, including ongoing frustrations with regulatory policies connected to developing land and building homes,' NAHB Chairman Buddy Hughes said in Monday's report. Still, Berkshire Hathaway revealed in regulatory filings last week that a handful of key homebuilder stocks were among Buffett's final plays. He's hardly alone in anticipating a rebound: During the first half of the year, Berkshire invested nearly $800 million in shares of homebuilder Lennar as well as roughly $300 million in homebuilder DR Horton; Lennar and DR Horton are two of just four homebuilders in the S&P 500. Berkshire also reported an approximately $857 million stake in Nucor, America's largest steelmaker. Meanwhile, a MarketWatch analysis of 18 homebuilders' stocks in the S&P Composite 1500 Index showed the group climbed 21% from the end of June through the end of last week, while the iShares US Home Construction ETF is up over 15% in the past month. Deep Cuts: So why the optimism? Demand-side softness is due almost entirely to one thing: affordability (or lack thereof), and a timely September rate cut from the Federal Reserve could help reduce prices for builders and buyers. The average rate on a 30-year fixed-rate mortgage fell to 6.58% last week, according to Freddie Mac. That's the lowest since October of last year and down from recent 7% highs. CME Group's FedWatch tool shows traders are penciling in an 83% chance of a quarter-point rate cut at the central bank's meeting in September, which could nudge mortgage rates down even further. Be careful, Jerome Powell: Disappointing the president is one thing, but the wrath of frustrated millennials may be even worse. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval
Cash truly is king. On Monday, shares in Novo Nordisk jumped 4% after the drugmaker announced that US customers who pay out-of-pocket will be able to buy its blockbuster diabetes drug Ozempic for less than half the list price. In a year of struggles against copycats, an emboldened chief rival and political pressure over high prices, executives are no doubt hoping the discount will prove a crowning achievement. READ ALSO: SoftBank Acquires a 2% Stake in Embattled Intel and Brokers Chafe Under Abrupt Expansion of Steel, Aluminum Tariffs A Letter from Washington Without insurance, Ozempic can set back US customers roughly $1,350 a month, or enough to rent a one-bedroom apartment in Kansas City (where the local barbecue might have you in need of a GLP-1 prescription). That hefty price tag has led to a bipartisan pushback in Washington, including from President Donald Trump, who sent a letter to Novo last month demanding executives lower prices for their company's treatments. Trump also urged drugmakers to develop direct-to-consumer sales models for their medicines. Americans spent $98 billion out of pocket on prescriptions last year, a 25% cumulative increase over five years, according to IQVIA, while a majority worry that prescription costs are unaffordable, according to KFF polling. Meanwhile, Novo has its own incentives to lower prices. For one, customers flocked to cheaper copycat drugs that exploded in popularity during a multi-year GLP-1 shortage, one that the FDA declared over earlier this year. And the company's chief rival in the GLP-1 space, Mounjaro- and Zepbound-maker Eli Lilly, has been binge-eating market share. Last month, the pressure prompted Novo to slash its sales and profit forecasts, prompting a massive selloff on Wall Street (shares are down 37% this year). On Monday, the company signalled it will defend its turf: Novo said cash-paying Americans can now buy Ozempic for $499 per month through its official website, its patient assistance program, its newly launched direct-to-consumer online pharmacy, or through discount telehealth platform GoodRx. The move follows Novo's decision to halve the price of weight-loss treatment Wegovy in March. Its price reductions follow similar cuts from Eli Lilly, which slashed the prices of both its weight loss and obesity GLP-1 drugs in March. David Ricks, Eli Lilly's CEO, said at the time that about 10% of the 1 million people who bought Zepbound did so from the company's website. MASHing Success: Monday's news came on the heels of a Friday victory for Novo, when Wegovy received FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), a liver condition that affects roughly 5% of US adults, potentially opening up a market of millions of new customers. It was the first GLP-1 treatment to be approved for MASH, giving Novo a leg up against its biggest competitor. Rival Lilly, meanwhile, has run trials, inked deals and even made an acquisition earlier this year with an eye to rolling out MASH treatments. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter.
Yahoo
38 minutes ago
- Yahoo
Feeding Westchester parts ways with CEO who led food bank through COVID uncertainty
ELMSFORD − After five years at the helm of Feeding Westchester during which the regional food bank doubled in size, President and CEO Karen C. Erren has parted ways with one of the region's largest nonprofits. A national search is under way to find her replacement. The news came in a Feeding Westchester press release Wednesday that noted Erren, "who led the organization through significant growth and expansion, has stepped down by mutual agreement." Efforts to reach Erren for comment were unsuccessful. Feeding Westchester CEO led food bank out of pandemic, doubled its size The departure comes one month after Erren's five-year anniversary. The Arkansas native arrived in July 2020 when uncertainty reigned in the grip of the pandemic. She and her staff navigated the unknowable, creating processes that kept food on tables of neighbors who were struggling the most. Working with a skeleton staff adhering to strict COVID-safety protocols, the food kept going out. Mobile food pantries offered families drive-thru services. Food pantry shelves were still stocked. This year, Feeding Westchester provided more than 21 million pounds of food to 175 food pantries. Erren stressed the need for fresh produce and on her watch the Elmsford warehouse was expanded greatly to accommodate fresh and shelf-stable offerings. In the statement announcing Erren's departure, the nonprofit's board of directors "expressed deep gratitude for her leadership and contributions to the organization's success over the past five years." Karen Erren: 'A well-fed man has many problems. A hungry man has one.' In July 2020, Erren arrived from Palm Beach, Florida, but her accent was all Arkansas Ozarks. In a May 2021 interview, she started many of her sentences with "You know, there's an old saying ..." in a homespun manner that pulled the listener in. She said she was fond of a certain bedrock saying: "A well-fed man has many problems. A hungry man has one." There is hunger in every community, every ZIP code, she said, adding, "Many days, I believe that there is hunger on every street.' Even in Westchester. 'Our neighbors who are hungry are just like you and me, but they don't have the family network or the safety net that so many of us have,' Erren said in the 2021 interview. 'Westchester County is a very wealthy community, but alongside great wealth is great need. And that has always been true.' Westchester food bank saw skyrocketing need in COVID times Food banks measure the volume of the problem in the number of meals, if not people, served. If a person visits multiple food pantries per week — which they tend to do, since a bag of groceries is intended to last three to five days — they are counted multiple times. Feeding Westchester's numbers skyrocketed in the early part of the pandemic, dwarfing pre-COVID rates. In February 2020, there were 130,000 client visits. By May 2020, that number had nearly tripled, to 354,000, the pandemic peak. According to the news release announcing Erren's departure, "In 2025, Feeding Westchester provided more than 21 million pounds of food equivalent to more than 17 million meals through soup kitchens, food pantries, schools, shelters, residential programs, and mobile distributions. That served an average of 234,000 neighbor visits." Tami Wilson will lead Feeding Westchester during national search for new CEO Chief Operating Officer Tami Wilson will lead Feeding Westchester during the national search for a new president and CEO, it was announced in the news release. The need remains acute as food insecurity shows no sign of abating in Westchester, one of the nation's wealthiest counties. More than one in three of the county's households is at risk of hunger, and deep cuts in federal funding threaten to make the situation even more dire, a reality noted by Vinay Rao, chair of the Feeding Westchester board. 'Feeding Westchester is entering a pivotal moment in its history. The Board is committed to finding a CEO who will amplify our mission and guide our organization confidently into the future,' Rao said. 'We are partnering with DSG Koya, a well-regarded executive recruitment leader, to conduct a thorough national search for a new CEO, guided by a shared commitment to Feeding Westchester's mission to serve our neighbors in need and working with our partners toward a Westchester where no one is hungry.' Peter D. Kramer is a 37-year staffer who writes long-form narratives on a variety of topics. His story looking back on the Oak Street fire in Yonkers won a national Headliner Award for outstanding news specials/feature column. Reach him at pkramer@ This article originally appeared on Rockland/Westchester Journal News: Feeding Westchester NY parts ways with CEO Karen Erren Solve the daily Crossword
